SLN earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.74. Updated 2026-07-23.
Silence Therapeutics (SLN) Research Hub
Silence Therapeutics (SLN) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 13.02 USD (-3.91%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.74, market cap 0.54B. This hub links to the full technical, earnings and options research available for SLN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 13.02 USD (-3.91%) |
| 52-week range | 6.61 USD – 16.52 USD |
| Trend regime | Range |
| 14-day RSI | 56.1 (Bullish) |
| Trailing P/E | -2.74 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for SLN
Covered Call on SLN: how it works, illustrative setup around the real 13.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SLN: how it works, illustrative setup around the real 13.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SLN: how it works, illustrative setup around the real 13.02 USD price, max profit/loss, breakeven and when to use it. Educational.
SLN technical analysis: range, last 13.02 USD, RSI 56.1, 52w range 6.61 USD–16.52 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SLN in?
Silence Therapeutics (SLN) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is SLN in an uptrend or downtrend?
As of 2026-09-11, SLN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SLN's trailing P/E ratio?
SLN's trailing P/E is -2.74, with a market cap of 0.54B. See the earnings research page for full valuation detail.
When does SLN next report earnings?
SLN is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.13866 USD.